Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure The ASTRONAUT Randomized Trial

JAMA The Journal of the American Medical Association (Impact Factor: 35.29). 03/2013; 309(11):1-11. DOI: 10.1001/jama.2013.1954
Source: PubMed


IMPORTANCE Hospitalizations for heart failure (HHF) represent a major health burden, with high rates of early postdischarge rehospitalization and mortality. OBJECTIVE To investigate whether aliskiren, a direct renin inhibitor, when added to standard therapy, would reduce the rate of cardiovascular (CV) death or HF rehospitalization among HHF patients. DESIGN, SETTING, AND PARTICIPANTS International, double-blind, placebo-controlled study that randomized hemodynamically stable HHF patients a median 5 days after admission. Eligible patients were 18 years or older with left ventricular ejection fraction (LVEF) 40% or less, elevated natriuretic peptides (brain natriuretic peptide [BNP] ≥400 pg/mL or N -terminal pro-BNP [NT-proBNP] ≥1600 pg/mL), and signs and symptoms of fluid overload. Patients were recruited from 316 sites across North and South America, Europe, and Asia between May 2009 and December 2011. The follow-up period ended in July 2012. INTERVENTION All patients received 150 mg (increased to 300 mg as tolerated) of aliskiren or placebo daily, in addition to standard therapy. The study drug was continued after discharge for a median 11.3 months. MAIN OUTCOME MEASURES Cardiovascular death or HF rehospitalization at 6 months and 12 months. RESULTS In total, 1639 patients were randomized, with 1615 patients included in the final efficacy analysis cohort (808 aliskiren, 807 placebo). Mean age was 65 years; mean LVEF, 28%; 41% of patients had diabetes mellitus, mean estimated glomerular filtration rate, 67 mL/min/1.73 m2. At admission and randomization, median NT-proBNP levels were 4239 pg/mL and 2718 pg/mL, respectively. At randomization, patients were receiving diuretics (95.9%), β-blockers (82.5%), angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (84.2%), and mineralocorticoid receptor antagonists (57.0%). In total, 24.9% of patients receiving aliskiren (77 CV deaths, 153 HF rehospitalizations) and 26.5% of patients receiving placebo (85 CV deaths, 166 HF rehospitalizations) experienced the primary end point at 6 months (hazard ratio [HR], 0.92; 95% CI, 0.76-1.12; P = .41). At 12 months, the event rates were 35.0% for the aliskiren group (126 CV deaths, 212 HF rehospitalizations) and 37.3% for the placebo group (137 CV deaths, 224 HF rehospitalizations; HR, 0.93; 95% CI, 0.79-1.09; P = .36). The rates of hyperkalemia, hypotension, and renal impairment/renal failure were higher in the aliskiren group compared with placebo. CONCLUSION AND RELEVANCE Among patients hospitalized for HF with reduced LVEF, initiation of aliskiren in addition to standard therapy did not reduce CV death or HF rehospitalization at 6 months or 12 months after discharge. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00894387.

Download full-text


Available from: Fabio Baschiera,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Heart failure (HF) remains a major medical problem, and the European Journal of Heart Failure is dedicated to publishing research further investigating its pathophysiology and diagnosis in order to help clinicians alleviate symptoms and improve patient outcomes.( 1) This review reports on important studies in the field of HF published in 2011. All research areas are addressed, including experimental studies, biomarkers, clinical trials, arrhythmias, and new insights into the role of device therapy.
    European Journal of Heart Failure 08/2012; 14(10):1090-6. DOI:10.1093/eurjhf/hfs121 · 6.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The American College of Cardiology's (ACC) 62(nd) Annual Scientific Session was held at the Moscone Center, San Francisco, from March 9-11, 2013. The meeting focused on the "transformation of cardiovascular care, from discovery to delivery", featured over 20 late-breaking clinical trials and 2,000 abstracts. These sessions gave notable exposure and recognition of studies likely to significantly affect clinical practice. There were 21 trials scheduled for presentation in 5 featured Late-Breaking Clinical Trial sessions, but one, the PREVAIL trial, was not presented because of a failure to observe an embargo. I summarize and overview both the late-breaking trials presented at ACC 2013 and the PREVAIL trial.
    Circulation Journal 04/2013; 77(5). DOI:10.1253/circj.CJ-13-0395 · 3.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: The renin-angiotensin-aldosterone system (RAAS) has long been established as a key pathway in the regulation of blood pressure and body fluid volume. The aspartic protease renin is responsible for the initial and rate-limiting step of the RAAS; hence inhibition of renin would favor an upstream blockade or modulation of the RAAS. Direct renin inhibitors (DRIs) are therefore considered attractive agents for the treatment of hypertension. However, the identification of orally bioavailable, efficacious and safe low molecular weight DRIs has proven very challenging. To date, aliskiren is the only DRI that has reached FDA approval as a hypertension therapy option. Areas covered: The present review summarizes the recent scientific accounts describing the design of new non-peptidic DRIs published between 2009 and 2012. The author also presents a number of chemical structures in addition to preclinical ADMET obtained from public scientific literatures and patent filings. Furthermore, the author discusses the results of early clinical trials of new candidate DRIs. Expert opinion: The vast medicinal chemistry efforts on structure-based design of non-peptidic DRIs, over the past 10 years, have presented new chemical spaces for tight binding to renin as well as gaining a proper balance between the physicochemical properties, potency, efficacy and safety. However, the criteria for candidate selection has become increasingly demanding; and new antihypertensives are expected to demonstrate a clear difference in their clinical profile beyond lowering blood pressure compared with established drug treatment paradigms.
    Expert Opinion on Drug Discovery 04/2013; 8(6). DOI:10.1517/17460441.2013.791279 · 3.54 Impact Factor
Show more